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Infectious diseases are the second leading cause of death world-
wide. Accordingly, there is an increasing need to identify new
antibacterial agents with a particular emphasis on multi-drug-
resistant bacteria and newly emerging pathogens. Evolution of
bacteria towards resistance to antimicrobial drugs, albeit an
unavoidable aspect of the general evolution of bacteria, is a major
public health concern as it is extremely difficult to overcome.1 New
hopes to delay the emergence and subsequent dissemination of
resistant microorganisms or resistant genes come from the discov-
ery of natural products that may act as efficient leads in the devel-
opment of novel therapeutic agents.2,3 Prominent amongst these
natural products are the members of the cationic host defence pep-
tide family, which are widely distributed in nature as a component
of the immediate non-specific defence against infections. This de-
fence peptide system exists in species of all kingdoms from insects
to plants to mammals and non-mammalian vertebrates and its
effectiveness has been assessed by demonstrating direct antimi-
crobial activity against bacteria, fungi, eukaryotic parasites and/ll rights reserved.
dermaseptin S1; FSC, fetal calf
amethyluronium hexafluoro-
anesulfonic acid; HPLC, high
nhibitory concentration; PBS,
n of peptides follow the rules
clature in J. Biol. Chem. 1972,
unless indicated otherwise.
x: +39 0532 455953.or viruses.4 The advantages of these peptides in clinical application
include their potential for broad-spectrum activity, their rapid bac-
tericidal activity and low propensity for development of resistance.
However, there are possible disadvantages such as cost, limited
stability and unknown toxicology.5
We focused on dermaseptins, a set of peptides expressed by dif-
ferent cells found in the skin of frogs belonging to the Phyllome-
dusinae subfamily.6–8 They consist of a characteristic polypeptide
chain of 28–34 amino acids with 3–6 lysine residues and a highly
conserved tryptophan residue in the third position from the N-ter-
minus. These peptides that differ in net charge and hydrophobicity
exert a selective lytic action on some bacteria, protozoa, yeast and
filamentous fungi at micromolar concentrations.8 Unlike polylysine
peptides, dermaseptins show little or no detectable haemolytic
activity.8,9 Using phospholipid liposomes or live cells the antimicro-
bial action of these peptides was shown to bemediated by selective
interaction of the basic and amphipathic a-helical moiety with
plasma membrane phospholipids, leading to permeabilization and
lysis.8,10,11 Recently, it has been demonstrated that dermaseptins
possess a potent spermicidal activity against human sperm.12 In
addition, some synthetic peptides derived from dermaseptin S4
showed activity against Neisseria gonorrhoeae13 indicating a poten-
tial role as microbicidal compounds. There has been renewed inter-
est in the antimicrobial activity of dermaseptins in response to the
isolation and characterization of DS 01, from the skin secretions of
the Brazilian species Phyllomedusa oreades, a novel dermaseptin
characterized by antibacterial and anti-protozoal activity.9,14
In this structure–activity relationship study, we chose derm-
aseptin S1 (DS1) because this peptide is characterized by the low-
est haemolytic activity.
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on dermaseptin S4 and its analogues.15,16 In contrast to other S
dermaseptin peptides, the 28-residue dermaseptin S4 is highly
toxic to erythrocytes but, as noted by Feder et al.15 and Rydlo
et al.16, reducing hydrophobicity or by increasing the net positive
charge improved peptide bioactivity. Shorter derivatives still dis-
played high antibacterial activity in vitro and in vivo along with
a more acceptable toxicity profile against human erythrocytes, al-
beit still rather high.17
In an attempt to explain why dermaseptins have markedly dif-
ferent biological activities despite a similar tendency to form
amphipathic helices, we synthesized a series of analogues of DS1.
In particular, we investigated the importance of the C-terminal
portion of DS1 on the growth of several microorganisms. Amongst
possible single residue changes we focused on position 3 (Trp3) to
assess the importance of the dermaseptin conserved indole moiety
on bioactivity.18 Here we report the design, synthesis and biologi-
cal evaluation of 15 DS1 analogues.2. Results and discussion
The main goal of our study was to identify a shorter bioac-
tive analogue of DS1 and then attempt to improve its biological
profile with respect to that of the parent peptide. In order to
fulfil this goal we used the following criteria: (i) progressive
C-terminal shortening (intact N-terminus is essential for antimi-
crobial activity7,8,19), (ii) perform single residue modifications on
the shortest active analogue, with particular emphasis on the
third residue.7,8
In order to characterize the antimicrobial properties of DS1 and
its analogues, Staphylococcus aureus and Escherichia coli were se-
lected as representative Gram-positive and Gram-negative bacte-
ria. The data obtained in the primary antimicrobial screening are
reported in Table 1. As mentioned above, in a first round of synthe-
sis the C-terminal portion of DS1 was progressively shortened and
amidated. Both chemical modifications are fully tolerated, as
shown by the fact that for peptides 1–3 the MIC concentration is
in the range from 2.7 to 35.9 lM. A small but consistent
increase in antimicrobial activity was observed for compound
DS1(1–29)-NH2, whilst deletion of residues beyond position 15 at
the C-terminus produces a marked decrease in biological activity.Table 1
Amino acid sequence, antibacterial activity and lysis of human red blood cells of DS1 and
N Compound Amino acid sequence
DS1 ALWKTMLKKLGTMALHAGKAALGAAADTISQG
1 DS1(1–29)-NH2 ALWKTMLKKLGTMALHAGKAALGAAADTI-NH
2 DS1(1–19)-NH2 ALWKTMLKKLGTMALHAG-NH2
3 DS1(1–15)-NH2 ALWKTMLKKLGTMAL-NH2
4 DS1(1–14)-NH2 ALWKTMLKKLGTMA-NH2
5 DS1(1–13)-NH2 ALWKTMLKKLGTM-NH2
6 DS1(1–12)-NH2 ALWKTMLKKLGT-NH2
7 [1Nal3]DS1(1–15)-NH2 AL-1Nal-KTMLKKLGTMAL-NH2
8 [2Nal3]DS1(1–15)-NH2 AL-2Nal-KTMLKKLGTMAL-NH2
9 [hPhe3]DS1(1–15)-NH2 AL-hPhe-KTMLKKLGTMAL-NH2
10 [Phe3]DS1(1–15)-NH2 AL-Phe-KTMLKKLGTMAL-NH2
11 [His3]DS1(1–15)-NH2 AL-His-KTMLKKLGTMAL-NH2
12 [Tyr3]DS1(1–15)-NH2 AL-Tyr-KTMLKKLGTMAL-NH2
13 [Leu3]DS1(1–15)-NH2 AL-Leu-KTMLKKLGTMAL-NH2
14 [Lys0]DS1(1–15)-NH2 Lys-ALWKTMLKKLGTMAL-NH2
15 [Lys01Nal3]DS1(115)-NH2 Lys-AL-1Nal-KTMLKKLGTMAL-NH2
Underline denote amino acids substitution performed on DS1(1–15)-NH2.
a MIC, minimal inhibitory concentration.
b LD50, dose responsible of the 50% lethality of bacteria after 3 h incubation.
c HD50, peptide concentration causing 50% lysis of human red blood cells.DS1(1–14)-NH2 is about fivefold less active than the reference
peptide on both Gram-positive and Gram-negative bacteria.
DS1(1–15)-NH2 is the minimum fragment showing antimicrobial
properties comparable to the parent peptide (DS1) both in terms
of MIC and LD50.
Having selected peptide DS1(1–15)-NH2 as a template for fur-
ther structure-activity investigations, we focused on the impor-
tance of the highly conserved tryptophan in position 38,18 on
antimicrobial activity. Replacement of the indole with a naphthyl
moiety generated compounds 7 and 8 that showed an antimicro-
bial potency comparable to that of the reference DS1(1–15)-NH2.
The presence of amino acids with a simple phenyl side chain (com-
pounds 9 and 10) in position 3 reduces antibacterial activity possi-
bly indicating that the distance between the side chain and the
peptide backbone seems to be particularly important in modulat-
ing activity against E. coli. Similar results were obtained replacing
Trp3 with amino acids characterized by different chemical entities,
1H-imidazole (compound 11), p-hydroxyphenyl (compound 12) or
isobutyl (compound 13) as side chain. Collectively, these data con-
firm the crucial role of position 3 for membrane bacterial interac-
tion and indicate as a critical feature the presence of an indole
nucleus. A key factor is probably the steric encumbrance of the side
chain, since Trp is believed to be a very good anchor point in the
membrane.20,21
In an attempt to improve the potency of DS1(1–15)-NH2 we
added a Lys residue to the N-terminus. Recent findings indicated
that acylation of dermaseptin S4 fragments with long chain fatty
acids, with or without an amino function in their structures, is well
tolerated in terms of antimicrobial activity and is instrumental in
modulating the potency and spectrum of activity in different assay
conditions.16,22 Compound 14 showed a small increase in MIC
against S. aureus and maintained the same activity as DS1(1–15)-
NH2 against E. coli. Interestingly, the LD50 against E. coli decreased
about twofold with respect to that of DS1(1–15)-NH2 indicating
faster bactericidal kinetics. The presence of an additional Lys resi-
due in the N-terminal peptide increases the positive charge with
respect to DS1(1–15)-NH2 and this may promote an interaction
with the cell wall of Gram-negative bacteria leading to a more
effective cell permeabilization. Combining in the same template
two modifications potentially able to increase antibacterial proper-
ties, that is, the replacement in position 3 with 1Nal and the addi-
tion to the N-terminal amino function of a Lys residue, yielded aanalogues
MICa (lM) LD50b (lM) HD50c (lM)
S. aureus E. coli S. aureus E. coli
TQ 12 12 5 3.1 >100
2 2.7 2.7 <1.5 2.2 >100
35.9 3.6 10.7 <1.8 >100
11.5 2.9 2.7 1.4 >100
>48.8 48.8 28.3 20.5 >100
>50.6 50.6 50.6 22.7 >100
>54 >54 54 54 >100
11.5 2.8 2.4 0.9 75
11.5 2.8 2.5 0.9 >100
46.8 11.7 9.3 3.0 >100
>47.1 23.5 16.7 4.5 >100
>44.9 >44.9 >44.9 >44.9 >100
>46.7 >46.7 >46.7 >46.7 >100
>47.9 23.9 12.0 6.0 >100
20.8 2.6 2.7 <0.8 >100
5.1 1.2 0.8 <0.8 80
Table 3
Activity of DS1 and C-terminal truncated analogues on Leishmania major
Compound MICa LC50b
lg/mL lM lg/mL lM
DS1 50 12 9.9 2.4
DS1(1–29)-NH2 25 6.1 9.6 2.3
DS1(1–19)-NH2 50 17.9 22 7.9
DS1(1–15)-NH2 50 22.8 19 8.7
DS1(1–14)-NH2 100 48.8 50 24.4
DS1(1–13)-NH2 100 50.6 50 25.3
DS1(1–12)-NH2 100 54.2 50 27.1
a MIC, minimal concentration inhibiting the growth of promastigotes after 24 h
incubation.
b LC50, concentration which caused a 50% reduction of survival or viability of
promastigotes after 24 h incubation.
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highly potent antimicrobial peptide against S. aureus and E. coli
with LD50 values in the sub-micromolar range. The values obtained
indicated an activity similar to that reported by Brand et al.9 and
was more potent than that reported by Rotem et al.23 with other
dermaseptin derivatives. This result indicated that different chem-
ical modifications can be combined in the same molecule with a fi-
nal synergistic effect on both MIC and LD50 values.
Cytotoxic activity of the synthesized peptides against human
RBC indicated 50% haemolysis (Table 1) at a peptide concentration
in excess of 75 lM, in most cases >100 lM, confirming that DS1 is
weakly haemolytic, possibly because the N-terminus is only mod-
erately hydrophobic.15 It is worthy of note that only with the com-
pounds 7, 8 and 15 at a concentration of 100 lM did haemolysis in
excess of 30% occur. With the other analogues, at the same concen-
tration, lytic activity was between 4% and 16%. These values are
substantially lower than that reported for other dermasep-
tins.9,24–26 DS1, DS1(1–15)-NH2 and analogues 7–15 were also
tested against different microorganisms, found in opportunistic
and chronic diseases and multi-drug-resistant (Table 2). In these
assays, the most active compounds (7, 8, 14 and 15) are character-
ized by the presence of the indole or naphthyl nucleus in position
3, by a further N-terminal Lys residue or, as in analogue 15, by the
presence of both chemical modifications in the template DS1(1–
15)-NH2. However, the activity of these peptides on multi-drug-
resistant bacteria was lower, and in particular the susceptibility
of Burkholderia cepacia and Stenotrophomonas maltophilia (two
Gram-negative non-fermenting strains) is very low. The antibacte-
rial behaviour of antimicrobial peptides is very likely to be dictated
by the nature of the external barriers of the microorganisms exam-
ined.6 Virulent strains of Pseudomonas aeruginosa may produce al-
ginic acid, a highly anionic capsular exopolysaccharide, that
interferes with antimicrobial activity of peptides in vitro.27 Along
with capsular shielding, this microorganism exploits other mecha-
nisms of resistance through inherent modifications of outer mem-
brane structures. Marr et al.5 and Yeaman and Yount27 reported
that Burkholderia (ex Pseudomonas sp.) was one of the few natu-
rally peptide-resistant organisms. In the multi-drug-resistant S.
aureus strain the lack of peptide activity could be due to the poly-
saccharidic capsule coating the peptidoglycan-based bacterial cell
wall, that sequesters the compound and neutralizes it prior to
reaching its target or to some constitutive alterations in cytoplas-
mic membrane structure or function.27 However, it is possible that
dermaseptins are involved in a process supporting other bacterial
targets, such as RNA synthesis, as reported by Patrzykat et al.28
The yeast Candida albicans was more susceptible to compounds
9 and 10, characterized by the presence of a phenyl ring in position
3 suggesting that this position may be useful for improving selec-
tivity against a selected pathogen. Moreover, in a preliminary as-
say, the first C-terminal truncated DS1 analogues were assayedTable 2
MIC evaluation of DS1, DS1(1-15)-NH2 (compound 3) and analogues against several Gram
Microorganism
DS 1 3 7 8
S. aureus ATCC 6538 P 6 5.7 2.8 2.8
S. aureus multi-drug-resistant NTb >47 22.5 >25
B. subtilis ATCC 9466 NTb 5.7 11.2 5.6
P. aeruginosa ATCC 15442 >24 >47 5.6 5.6
P. aeruginosa multi-drug-resistant NTb >47 11.2 11.2
B. cepacia 6/06 >24 23.7 25 25
Stenotrophomonas maltophilia FC >24 >45 22.5 25
C. albicans >24 23.7 11.2 11.2
a MIC, minimal inhibitory concentration.
b NT, not tested.against Leishmania major. The results reported in Table 3 are ob-
tained after 24 h incubation of the protozoon with different pep-
tides. Similar inhibitory and killing activities were observed after
3 h of treatment. We also observed dose-dependent activity
against L. major promastigotes (data not shown). Standard devia-
tions of LC50 were 610% of the values reported. These results dem-
onstrate that in this assay shortening of the C-terminal peptide
sequence seems to have a detrimental effect against the leishman-
icidal activity and the sequence 1–29 appears to be the minimal ac-
tive fragment. Compounds DS1(1–29)-NH2 had a LC50 similar or
marginally increased to that of DS1 and dermaseptin S4 as re-
ported by Gaidukov et al.24 on L. major, and also increased com-
pared to temporins A and B reported by Mangoni et al.29 on L.
donovani. Moreover, leishmanicidal activity was observed at con-
centrations significantly lower than RBC cytotoxic concentrations
indicating more selectivity compared to the dermaseptin ana-
logues tested by Gaidukov et al.24
The antimicrobial activity observed by some of the synthetic
compounds tested are similar to those obtained by other authors
with defensins30 and with peptides purified from Phyllomedusa dis-
tincta.31 However, at least 15 amino acids (or 14 with changes in
the initial part of the molecule) are required to display potent
activity against bacteria and Candida.
The anti-protozoal activity was superior with native dermasep-
tin (34 aa) or derivatives with a long chain (29 aa), without a par-
allel haemolytic activity. Similarly, Brand et al.9 demonstrated an
anti-protozoal activity against Trypanosoma cruzi by DS01 (29-res-
idue peptide) and by two synthetic derivatives, without a toxicity
against mouse erythrocytes and white blood cells. The observed
activity seems superior to that reported by Mangoni et al.29 for
temporins (from Rana temporaria).
Leishmaniasis is a significant health problem in many regions of
the world, especially as it has high prevalence in HIV positive pa-
tients.32 As there is currently a limited number of chemotherapeu--positive and Gram-negative bacteria and the yeast Candida albicans
MICa (lM) of different peptides
9 10 11 12 13 14 15
5.8 23 >45 >45 24 2.6 1.3
>46 >46 >45 >45 >48 >42 21
23 23 >45 >45 24 21 5.2
>46 >46 >45 >45 >48 5.2 2.6
46 >46 >45 >45 >48 21 10.5
23 >46 >45 >45 >48 42 42
23 >46 >45 >45 >48 21 21
5.8 5.8 >45 >45 12 10.4 10.5
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rola et al.33) dermaseptin analogues represent a novel approach
worthy of further investigation.
3. Conclusion
Investigating the structure–activity features of DS1, we identi-
fied that (i) the minimum bioactive sequence is the DS1(1–15)-
NH2; (ii) the Trp in position 3 is important for biological activity
and can be substituted with non-natural amino acids bearing a
naphthyl nucleus on the side chain; (iii) a further Lys residue in
the N-terminal improves the antimicrobial activity against E. coli
and (iv) modifications in position 3 and the N-terminus can be
combined in the DS1(1–15)-NH2 template to generate novel anti-
microbial peptides. Some of these novel small synthetic peptides
(belonging to the family of dermaseptins) revealed a selective
activity against some microorganisms indicating a potential use
as new selective antimicrobials.Table 4
Abbreviated names and analytical properties of DS1 and analogues
No. Abbreviated names tRa MH+b
I II Calculated Found
DS1 12.31 26.22 3456.6 3456.2
1 DS1(1–29)-NH2 12.66 26.93 2953.6 2953.0
2 DS1(1–19)-NH2 11.86 23.90 2098.2 2098.2
3 DS1(1–15)-NH2 13.06 25.33 1705.2 1705.1
4 DS1(1–14)-NH2 11.05 23.24 1592.2 1592.3
5 DS1(1–13)-NH2 11.07 22.97 1520.3 1520.6
6 DS1(1–12)-NH2 10.30 21.51 1389.3 1389.6
7 [1Nal3]DS1(1–15)-NH2 10.02 20.60 1715.3 1715.8
8 [2Nal3]DS1(1–15)-NH2 9.86 19.42 1715.3 1715.0
9 [hPhe3]DS1(1–15)-NH2 9.78 20.15 1680.2 1680.7
10 [Phe3]DS1(1–15)-NH2 9.54 19.73 1666.2 1666.7
11 [His3]DS1(1–15)-NH2 9.51 17.49 1655.1 1655.8
12 [Tyr3]DS1(1–15)-NH2 9.43 18.32 1682.2 1682.3
13 [Leu3]DS1(1–15)-NH2 9.67 19.44 1632.2 1632.6
14 [Lys0]DS1(1–15)-NH2 9.67 19.41 1832.4 1832.8
15 [Lys01Nal3]DS1(1–15)-NH2 9.58 16.65 1844.2 1844.8
a tR is the retention time determined by analytical HPLC.
b The mass ion (MH+) was obtained by electro spray mass spectrometry.4. Experimental
4.1. General information
Amino acids, protected amino acids, and chemicals were pur-
chased from Bachem, Novabiochem, Fluka or Chem-Impex Interna-
tional. All other reagents were from Sigma Chemical Co. (Poole, UK)
or E. Merck (Darmstadt, Germany) and were of the highest purity
available. Peptides were stored as a lyophilized powder at
20 C. Solutions were prepared in PBS, vortexed, and used as
stock solutions in experiments.
4.2. Peptide synthesis
All the peptides were synthesized by solid-phase methods using
Fmoc/tBu chemistry34 with a SYRO XP synthesizer (MultiSyntech,
Witten Germany). Rink resin (0.65 mM/g) and Wang resin preload-
ed with Fmoc-Gln(Trt) (0.45 mM/g) (Fluka, Buchs SG, Switzerland)
were used as a support for the synthesis of peptides as amide or
free acid, respectively. The resin (0.2 g in all synthesis) was treated
with piperidine (20%) in DMF and the Fmoc amino acid derivatives
(fourfold excess) were coupled to the growing peptide chain using
HATU35 (fourfold excess). Piperidine (20%) in DMF was used to re-
move the Fmoc group at all steps.
After deprotection of the last Fmoc group, the peptide resin was
washed with methanol and dried in vacuo to yield the protected
peptide-Resin. Protected peptides were cleaved from the resin by
treatment with Reagent B36 TFA/phenol-triisopropysilane/H2O
(88:5:2:5 v/v) 5 mL/0.2 g of resin at room temperature for 2 h.
After filtration of the resin, the solvent was concentrated in vacuo
and the residue triturated with ether. The crude peptides were
purified by preparative reverse phase HPLC to yield a white pow-
der after lyophilization.
4.3. Peptide purification and analytical determinations
Crude peptides were purified by preparative reversed-phase
HPLC using a Waters Delta Prep 4000 system with a Phenomenex
Jupiter C18 column (250  30 mm, 300 A, 15 lm spherical particle
size column). The column was perfused at a flow rate of 25 mL/min
with solvent A (10%, V/V, acetonitrile in 0.1% aqueous TFA), and a
linear gradient from 0% to 60% of solvent B (60%, V/V, acetonitrile
in 0.1% aqueous TFA) over 25 min was adopted for peptide elution.
Analytical HPLC analyses were performed on a Beckman 125 liquid
chromatograph equipped with a Beckman 168 diode array detec-
tor. Analytical purity and retention time (tR) of the peptides weredetermined using two different HPLC conditions. Retention time I
was obtained using a Alltech C18 column (4.6  150 mm 5 lm par-
ticle size) with the above solvent system (solvents A and B) pro-
grammed at a flow rate of 1 mL/min using a linear gradient from
5% to 50% B over 25 min. Retention time II was obtained using a
TSK gel super ODS C18 column (4.6  150 mm, 5 lm particle size)
with solvent A: 35 mM NaH2PO4 (pH 2.1) and solvent B: 59 mmol
NaH2PO4 (pH 2.1)/acetonitrile (60:40 v/v). The column was per-
fused at a flow rate of 1 mL/min with a linear gradient from 0%
to 30% B over 25 min. All analogues showed >95% purity when
monitored at 220 nm. Molecular weights of compounds were
determined using a mass spectrometer ESI Micromass ZMD-
2000; values are expressed as MH+. The analytical properties of
DS1 analogues are reported in Table 4.
4.4. Antibacterial activity
In the first series of experiments two bacterial strains (S. aureus
Cowan 1 NCTC 8530 and E. coli HB101), one Gram-positive and one
Gram-negative, were used to investigate antimicrobial activity.
Microorganisms were grown in static culture at 37 C in Mueller
Hinton Broth (Oxoid) and diluted to 5  105 CFU/mL. The MIC
was determined using the microdilution serial twofold assay (from
100 lg/mL of each preparation) and performed in sterilized 96-
well plates (Nunc) in a final volume of 200 lL16,37; control wells
without peptides were included. The MIC was considered the low-
est peptide concentration that showed no increase in turbidity
after overnight incubation at 37 C. To evaluate bactericidal kinet-
ics, another series was prepared and incubated for 3 h; afterwards,
the cultures were subjected to serial 10-fold dilutions in PBS and
bacterial counts were determined after 24 h incubation at 37 C
in Mueller Hinton Agar (Oxoid) plates. Peptide dose causing 50%
lethality (LD50) was assessed.15 More active compounds were as-
sessed for the MIC against several other bacteria, three Gram-posi-
tive (S. aureus ATCC 6538P, S. aureus multi-drug-resistant and
Bacillus subtilis ATCC 9466) and four Gram-negative (P. aeruginosa
ATCC 15442, P. aeruginosa multi-drug-resistant, B. cepacia 6/06
and Stenotrophomonas maltophilia FC). All results represent the
mean values obtained from at least two independent experiments
performed in duplicate.
4.5. Antifungal assay
One yeast species, C. albicans (wild strain), was assayed. The in
vitro assay (in triplicate) was performed using the broth microdilu-
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Pfaller et al.39 The MIC was considered the lowest peptide concen-
tration that showed no increase in turbidity after overnight incuba-
tion at 37 C.
4.6. Haemolytic activity
Investigation of haemolytic activity was essentially as re-
ported.9,31 The compounds were serially diluted in Eppendorf test
tubes and incubated under agitation with 100 lL containing 108
human red blood cells (RBC), obtained from human washed blood,
at 37 C for 30 min. After a 900g centrifugation for 10 min, the
absorbance of the supernatant (as an index of haemoglobin leak-
age) was measured spectrophotometrically (Microplate Reader
450, Bio-Rad) at 550 nm. Maximum haemolysis was determined
by adding distilled water. The peptide concentration (mean) caus-
ing 50% lysis (HC50) was obtained from at least two independent
experiments performed in triplicate.
4.7. Leishmanicidal activity
Leishmania major (strain MHOM/IL/67/JERICHO-II) promastig-
otes were grown at 25 C in ‘complete medium’37,40, comprising
medium 199 (Invitrogen, California, USA) supplemented with
20% heat-inactivated FCS (Invitrogen), 100 U/mL penicillin,
100 lg/mL streptomycin, 2 mM L-glutamine, 40 mM HEPES,
0.1 mM adenine (in 50 mM HEPES), 5 lg/mL hemin (in 50% trieth-
anolamine) and 1 lg/mL 6-biotin (in 95% ethanol) L. major were
resuspended in fresh medium to a final concentration of 5  105
viable promastigotes/mL and treated with serial dilutions of the
different peptides. Protozoal viability was assessed after 3 and
24 h incubation at 25 C under agitation by counting in a haemocy-
tometer (Thoma chamber) after vital staining with trypan blue
(dye exclusion method). The experiments were performed in trip-
licate and the results reported as mean of the MIC values. The pep-
tide concentration which caused a 50% reduction in survival or
viability (LC50) after 24 h incubation in comparison to that in an
identical culture without the compound was estimated. This value
was determined by nonlinear regression analysis using GraphPad
Prism 3 software. Standard deviation of LC50 was 610% of the val-
ues reported.
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